PT3445351T - Acetil-leucina ou um sal farmaceuticamente aceitável seu derivado para melhoria da mobilidade - Google Patents

Acetil-leucina ou um sal farmaceuticamente aceitável seu derivado para melhoria da mobilidade

Info

Publication number
PT3445351T
PT3445351T PT177196920T PT17719692T PT3445351T PT 3445351 T PT3445351 T PT 3445351T PT 177196920 T PT177196920 T PT 177196920T PT 17719692 T PT17719692 T PT 17719692T PT 3445351 T PT3445351 T PT 3445351T
Authority
PT
Portugal
Prior art keywords
leucine
acetyl
pharmaceutically acceptable
acceptable salt
cognitive function
Prior art date
Application number
PT177196920T
Other languages
English (en)
Portuguese (pt)
Original Assignee
Intrabio Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Intrabio Ltd filed Critical Intrabio Ltd
Publication of PT3445351T publication Critical patent/PT3445351T/pt

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/195Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicinal Preparation (AREA)
PT177196920T 2016-04-19 2017-04-19 Acetil-leucina ou um sal farmaceuticamente aceitável seu derivado para melhoria da mobilidade PT3445351T (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB201606834 2016-04-19

Publications (1)

Publication Number Publication Date
PT3445351T true PT3445351T (pt) 2024-11-14

Family

ID=58633040

Family Applications (1)

Application Number Title Priority Date Filing Date
PT177196920T PT3445351T (pt) 2016-04-19 2017-04-19 Acetil-leucina ou um sal farmaceuticamente aceitável seu derivado para melhoria da mobilidade

Country Status (27)

Country Link
US (4) US10905670B2 (enExample)
EP (2) EP3445351B1 (enExample)
JP (3) JP7387264B2 (enExample)
KR (4) KR102413754B1 (enExample)
CN (2) CN109069463B (enExample)
AU (2) AU2017252507B2 (enExample)
BR (1) BR112018071547A2 (enExample)
CA (1) CA3021155A1 (enExample)
DK (1) DK3445351T3 (enExample)
ES (1) ES2994242T3 (enExample)
FI (1) FI3445351T3 (enExample)
HR (1) HRP20241552T1 (enExample)
HU (1) HUE069219T2 (enExample)
IL (3) IL310508A (enExample)
LT (1) LT3445351T (enExample)
MD (1) MD3445351T2 (enExample)
MX (2) MX388461B (enExample)
NZ (1) NZ747307A (enExample)
PL (1) PL3445351T3 (enExample)
PT (1) PT3445351T (enExample)
RS (1) RS66142B1 (enExample)
RU (1) RU2745912C2 (enExample)
SG (2) SG11201809031XA (enExample)
SI (1) SI3445351T1 (enExample)
SM (1) SMT202400459T1 (enExample)
WO (1) WO2017182802A1 (enExample)
ZA (1) ZA201806849B (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102413754B1 (ko) * 2016-04-19 2022-06-27 인트라바이오 리미티드 이동성 및 인지 기능을 개선시키기 위한 아세틸-류신 또는 이의 약제학적으로 허용되는 염
PL3416631T3 (pl) 2016-08-11 2019-11-29 Intrabio Ltd Środki terapeutyczne do leczenia chorób neurodegeneracyjnych
GB201709459D0 (en) 2017-06-14 2017-07-26 Intrabio Ltd Treatment for migraine
WO2020115715A1 (en) 2018-12-06 2020-06-11 Intrabio Ltd. Deuterated analogs of acetyl-leucine
IL321899A (en) * 2019-03-02 2025-09-01 Intrabio Ltd Leucine, acetyl leucine and related analogs for the treatment of disease
US20250099355A1 (en) * 2023-07-18 2025-03-27 Sytheon Ltd Amino acid based salts, compositions and methods for treating skin and improving skin rejuvenation and longevity
US12403111B2 (en) 2024-02-02 2025-09-02 SynGAP Research Fund Compositions and methods for treating neurodevelopmental disorders

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060063827A1 (en) * 2004-09-23 2006-03-23 Yu Ruey J Systemic administration of therapeutic amino acids and N-acetylamino acids
US20070190070A1 (en) * 2004-09-03 2007-08-16 Zeldis Jerome B Methods of using and compositions comprising selective cytokine inhibitory drugs for the treatment and management of disorders of the central nervous system
FR2883180B1 (fr) * 2005-03-18 2007-05-25 Pierre Fabre Medicament Sa Utilisation de l'acetyl-leucine pour la preparation d'un medicament destine au traitement de troubles de l'equilibre
FR2905600B1 (fr) * 2006-09-13 2010-01-15 Pf Medicament Traitement des vertiges par l'acetyl-l-leucine.
US20080097606A1 (en) * 2006-10-19 2008-04-24 Cragg Andrew H Knee joint prosthesis and hyaluronate compositions for treatment of osteoarthritis
EP2152280A1 (en) * 2007-05-08 2010-02-17 Northern Innovations And Formulations Corp. Branched-chain amino acid composition for improving skeletal muscle protein metabolism
WO2011025518A1 (en) * 2009-08-27 2011-03-03 Albert Einstein College Of Medicine Of Yeshiva University Cognitive function training to improve motor ability
TN2010000251A1 (fr) * 2010-06-03 2011-11-11 Rekik Raouf N-acetyl-dl-leucine medicament neuro et retino protecteur
WO2012060844A1 (en) * 2010-11-05 2012-05-10 Biotie Therapies, Inc A2a antagonists as cognition and motor function enhancers
TN2010000566A1 (en) * 2010-12-03 2012-05-24 Rekik Raouf Folic acid - ramipril combination : cell protective neuroprotective and retinoprotective ophtalmologic drugs
KR102413754B1 (ko) 2016-04-19 2022-06-27 인트라바이오 리미티드 이동성 및 인지 기능을 개선시키기 위한 아세틸-류신 또는 이의 약제학적으로 허용되는 염
US12458614B2 (en) * 2017-10-18 2025-11-04 Intrabio Ltd Therapeutic agents for improved mobility and cognitive function and for treating neurodegenerative diseases and lysosomal storage disorders

Also Published As

Publication number Publication date
MD3445351T2 (ro) 2024-12-31
RU2018140131A3 (enExample) 2020-05-14
MX2021014844A (es) 2022-01-18
CN118593463A (zh) 2024-09-06
LT3445351T (lt) 2024-11-25
KR20240018683A (ko) 2024-02-13
MX2018012739A (es) 2019-06-17
EP3445351B1 (en) 2024-10-16
RU2021107001A (ru) 2021-04-12
KR20220038814A (ko) 2022-03-29
SG11201809031XA (en) 2018-11-29
KR20180134398A (ko) 2018-12-18
SMT202400459T1 (it) 2025-01-14
NZ747307A (en) 2025-10-31
RU2018140131A (ru) 2020-05-14
JP2024123087A (ja) 2024-09-10
JP2019513814A (ja) 2019-05-30
EP4501406A2 (en) 2025-02-05
RU2745912C2 (ru) 2021-04-02
KR102413754B1 (ko) 2022-06-27
US11998518B2 (en) 2024-06-04
IL293266B2 (en) 2024-07-01
IL262379B (en) 2022-07-01
WO2017182802A1 (en) 2017-10-26
FI3445351T3 (fi) 2024-11-18
IL293266A (en) 2022-07-01
KR102791288B1 (ko) 2025-04-03
HRP20241552T1 (hr) 2025-01-17
MX388461B (es) 2025-03-20
US20210106548A1 (en) 2021-04-15
IL293266B1 (en) 2024-03-01
BR112018071547A2 (pt) 2019-03-06
AU2017252507A1 (en) 2018-11-08
US20230346732A1 (en) 2023-11-02
KR20220093386A (ko) 2022-07-05
CA3021155A1 (en) 2017-10-26
US20190083438A1 (en) 2019-03-21
US20250332133A1 (en) 2025-10-30
HUE069219T2 (hu) 2025-02-28
EP3445351A1 (en) 2019-02-27
IL310508A (en) 2024-03-01
JP7506046B2 (ja) 2024-06-25
KR102632670B1 (ko) 2024-02-01
AU2017252507B2 (en) 2022-07-21
DK3445351T3 (da) 2024-11-04
CN109069463B (zh) 2024-07-23
SI3445351T1 (sl) 2025-04-30
EP4501406A3 (en) 2025-03-26
RS66142B1 (sr) 2024-12-31
SG10202106190RA (en) 2021-07-29
JP7387264B2 (ja) 2023-11-28
ES2994242T3 (en) 2025-02-05
AU2022256077A1 (en) 2022-11-17
US12329733B2 (en) 2025-06-17
IL262379A (en) 2018-11-29
US10905670B2 (en) 2021-02-02
JP2022024058A (ja) 2022-02-08
PL3445351T3 (pl) 2025-01-07
CN109069463A (zh) 2018-12-21
ZA201806849B (en) 2019-07-31

Similar Documents

Publication Publication Date Title
IL262107B (en) Overlapping bangs
ZA202103713B (en) Mobility procedure
SG10202106190RA (en) Acetyl-leucine or a pharmaceutically acceptable salt thereof for improved mobility and cognitive function
HUE049523T2 (hu) Peszticidként hatásos szemikarbazon- és tioszemikarbazon-származékok
LT3672948T (lt) Piridinamino-piridono ir pirimidinamino-piridono junginiai
ZA201904241B (en) Novel compound and pharmacologically acceptable salt thereof
IL270011B (en) Medicinal compounds and methods
GB201617064D0 (en) Compounds and their therapeutic use
IL272385A (en) Drug compound and methods of preparation
NO2024058I1 (no) delgocitinib or a pharmaceutically acceptable salt thereof
ZA201805743B (en) Hla-b57 open conformers
GB201616370D0 (en) Wireless handover system
IL292482B2 (en) Azaindolylpyridone and diazaindolylpyridone compounds
IL267937A (en) Amide compounds and their use
IL265269B (en) New compounds and their medicinal uses
ZA201806247B (en) Beta-caseins and cognitive function
GB201700404D0 (en) Compounds and composistions
GB2539264B (en) Mobility aid
GB201720115D0 (en) Mobility aid
GB201617063D0 (en) Condoms
IL265617B (en) 1-phenylpropanone compounds and their use
PT3630997T (pt) Monitorização terapêutica de fármacos
GB201702051D0 (en) New Pharmaceutical use
GB201700872D0 (en) A bed mobility aid
GB201619949D0 (en) nOMV-antigen conjugated compounds and use thereof